Italian reagent rental bill rejected:
This article was originally published in Clinica
The Italian bill on reagent rental plans was narrowly defeated by the select affairs committee in the Social Affairs Commission of the Italian Parliament. It failed to gain approval by 16 votes to 15, with the PDS and Lega parties rejecting the text. A new rapporteur is being appointed to the committee before the bill is voted on again. Vittorio Lodolo D'Oria, the Forza Italia coalition party deputy who was instrumental in developing the law, had been the rapporteur. A spokesman for his office expressed optimism that the bill would be approved before the end of the year.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.